Our leadership team has experience throughout the drug development process, from drug discovery through to commercialization
Chief Executive Officer
Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman of our Board since February 2020. Mr. Duggan has served as our Chief Executive Officer since April 2020.
Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm. His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases that extend patients’ lives.
From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers. Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical, Inc. From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.
Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985. In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.
Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse BioSciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.
Chief Operating Officer
Dr. Maky Zanganeh has served as Summit’s Chief Operating Officer and has been a member of the Board of Directors since November 2020.
She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.
Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”), which provides consulting services to businesses in product development, research, and transactions.
Prior to starting and leading MZA, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.
Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013. She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).
Beyond Summit, Dr. Zanganeh is currently a board member for Pulse BioSciences, Inc. and RenovoRx, Inc.
Chief Scientific Officer
Dr. Dave Powell joined Summit from GSK where he served as Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.
Dr. Powell held a number of positions of increasing seniority in his time at GSK. As part of his work there, he participated in antibiotic discovery, assay development, high throughput screening design and implementation, and lead optimisation support. In his most recent role at GSK, he led a collaboration with the Crick Institute, in addition to providing support to GSK’s ‘Discovery Partnerships with Academia’ team which collaborated with academic groups in downstream drug discovery. He was awarded a BSc and MSc from the National University of Ireland Galway, before completing a PhD in biochemistry at Cardiff University.
Chief Financial Officer
Mr. Donaldson joins Summit from Goldfinch Bio, Inc., where he led finance and accounting as Vice President, Finance, and Corporate Controller. Previously, he served as Vice President, Finance, Corporate Controller and Assistant Treasurer at ARIAD Pharmaceuticals, Inc., which was acquired by Takeda in February 2017. Prior to that, he was the Corporate Controller for Hittite Microwave Corporation, which was acquired by Analog Devices in July 2014. Mr. Donaldson spent the first 11 years of his career at PricewaterhouseCoopers. He received his undergraduate degree in accounting and information systems from the University of Massachusetts and is a Certified Public Accountant in Massachusetts.
Head of IT
VP, Investor Relations & Corporate Strategy
Dave Gancarz, CPA, is our VP of Investor Relations and Corporate Strategy who provides strategic leadership and communication on our company’s corporate affairs, strategy, and endeavors to our various stakeholders. Mr. Gancarz’s previous experience focuses in on commercial finance, general corporate finance, and accounting.
Mr. Gancarz joined Summit from Athenahealth, Inc., where he most recently led the commercial finance team, where he oversaw the company’s overall pricing strategy, deal pricing, deal administration, and sales operations functions. Prior to that, he held leadership positions in accounting at Athenahealth. Mr. Gancarz began his career at PricewaterhouseCoopers, where he was a Senior Manager in the Boston, MA and Miami, FL offices. Mr. Gancarz received his MSA and BSBA degrees from Stonehill College in Easton, MA, and is a Certified Public Accountant in Massachusetts and Florida.
Head of Clinical Affairs
Camilla S. Graham, MD, is our Head of Clinical Affairs who provides strategic leadership and communication on our key priority assets and product value. An infectious disease specialist, she has practiced since 2001 at Beth Israel Deaconess Medical Center and is on faculty at Harvard Medical School in Boston, MA.
Additionally, Dr. Graham has 14 years of experience straddling academic medicine and the pharmaceutical industry, including leading the launch of INCIVEK® (telaprevir) and KALYDECO® (ivacaftor) as the Global Head of Medical Affairs at Vertex Pharmaceuticals, and advising numerous state and federal government agencies on access to medications on the academic side.
Dr. Graham received her MD from Medical College of Pennsylvania, Philadelphia, PA, and her MPH from Harvard School of Public Health, Boston, MA.
Head of Human Resources
Campbell Hair is our Head of Human Resources, and is an HR leader with over thirty years’ experience. Most recently, Mr. Hair was the CHRO at Ciklum. Ciklum was an international software development and IT outsourcing company owned by George Soros. It was headquartered in London but with software development centres primarily based in Ukraine and other Eastern European countries.
Prior to Ciklum, Mr. Hair was CHRO for Xchanging in the UK, which grew from five hundred employees in the UK to over eight thousand employees in over fifteen countries across South East Asia, North America and Europe. Mr. Hair’s early career began at Ford Motor Company, where he undertook a number of different HR roles including in Manufacturing, Product Development, Sales, and IT working across Europe and the US.
Mr. Hair has a BSc in Business Studies and a Master of Law (LLM) degree in European Employment Law from Leicester University.
Head of Medical Science
John K. John
Head of Quality Assurance
John K. John serves as our Head of Quality Assurance. He is responsible for global GxP quality and regulatory compliance. He is responsible for global GxP quality and regulatory compliance.
Mr. John has 30 years of GxP quality and auditing experience in the biopharmaceutical and medical device industry. He was part of teams within various companies that brought several drug products to market from clinical trials to commercialization. These included SEROTISM®, HUMIRA®, VIGAMOX®, CIPRODEX®, HERCEPTIN®, HYLENEX®, MUCINEX®, and XERMELO®. He is a Subject Matter Expert for GxP quality and aseptic processing.
During his career, Mr. John has hosted numerous global regulatory agencies for drug Pre-Approval Inspections (PAIs). Most recently, Mr. John and his team received drug approval to commercialize Xermelo® both from the US FDA and EMA.
Mr. John holds a Master of Science degree in Microbiology from the University of Bridgeport, CT, USA.
Head of Regulatory Affairs
Head of Clinical Operations
Deepali Suri is Head of Clinical Operations and Project Management at Summit. Deepali is a Clinical Development Leader recognized for strategic development and implementation of global clinical programs in multiple therapeutic indications.
Deepali has experience spanning 20 years leading high performance operations teams in delivery of complex clinical trials. Prior to joining Summit, Deepali was Head of Clinical Operations, Clinical Data Management, and Clinical Drug Supply Operations at Sunesis Inc. Prior to Sunesis, Deepali was an Executive Director at Pharmacyclics, leading Clinical Operations and execution of IMBRUVICA® (ibrutinib) trials. Deepali led multiple studies and study teams in Phase II-III Imbruvica® programs from startup through regulatory approvals in CLL, SLL, MZL, and Solid Tumors to ensure that the study deliverables were achieved per the set milestones. Deepali was Recipient of AbbVie’s highest honor, the Chairman’s Award, for exemplary leadership on Imbruvica® Phase III CLL program.
Deepali has Master’s degree in Pharmacology from University of Delhi (India).
Head of CMC & Supply Chain
Laura Trespidi, PhD, is our Head of CMC and Supply Chain, who provides strategic leadership for all CMC product development activities and end-to-end Supply Chain and Technical Operations functions. Dr. Trespidi has over 28 years’ experience in product development and external manufacturing across several dosage forms, therapeutic areas, and team leadership.
Additionally, Dr. Trespidi has led global CMC and External Manufacturing teams through all stages of product lifecycle at Mundipharma, Shire Pharmaceutical, and GSK. She is recognized for her Extensive knowledge of global regulation and guidelines that impact the chemistry and manufacturing of pharmaceutical products. She led interactions with global RA Agencies and attended mora than 20 international Quality audits. She is a Subject Matter Exert (SME) for technical due diligences. She led multidisciplinary Late and Early Development Product Strategy teams. Dr. Trespidi is a pioneer of the external development and manufacturing model and a real expert in outsourcing CMC activities and commercial manufacturing.
Dr. Trespidi holds a PhD in Pharmaceutics from the School of Pharmacy, University of Milan (Italy).
Head of Patient Safety & Pharmacovigilance
Deepa Venkataraman is our Head of Global Patient Safety and Pharmacovigilance who provides global strategic, scientific, and operational leadership. She comes with extensive experience in Patient Safety, Clinical Development, Research, Quality, and strategic leadership spanning over 18 years. Her most recent role was at AbbVie as the Head of Global Case Management, Global Medical Coding, and Medical Safety Review organization. She had built a highly talented Pharmacovigilance function from ground up at Pharmacyclics (acquired by AbbVie in 2015), led the team thru 11 approvals for IMBRUVICA® (ibrutinib) for over 7.5 years, grew the team 50-fold and led the successful integration with AbbVie in 2019. Prior to Pharmacyclics, Ms. Venkataraman was at Johnson & Johnson, where she contributed towards successful launch of INCIVO® (telaprevir), ZYTIGA® (abiraterone acetate), INVOKANA® (canagliflozin), and NUCYNTA® (tapentadol).
Through her innovative work, Ms. Venkataraman has received several awards and recognition and was nominated in 2019 for FiercePharma’s “50 Fiercest Women in Life Sciences” award. She is an active and passionate public speaker at various high-profile Safety and Women leadership congresses.
Ms. Venkataraman received her Master’s Degree in Pharmacy with specialization in Medical Chemistry from Rajiv Gandhi University (India).